Bruce D. Forrest

For over 25 years, Dr. Forrest worked as a pharmaceutical industry physician leading the global development of pharmaceuticals, vaccines, and biological drugs.

As Senior Vice President at Wyeth Vaccines, Dr. Forrest was responsible for all late-phase clinical and pharmaceutical science development activities for vaccines in the Wyeth pipeline, including Prevnar 13®; the meningococcal B vaccine (Trumemba), and an early investigational Staphylococcus aureus vaccine. This role included managing a vaccines’ development organization situated in North Carolina and New York, responsible for all R&D CMC and Manufacturing activities. In addition,

Dr. Forrest was responsible for management and oversight of all Vaccines Clinical Research clinical trial and development activities globally with a dedicated vaccines clinical staff. He led the clinical activities supporting the market authorization for RotaShield (EU), Prevnar (Global), and FluMist.

Dr. Forrest also served as the Corporate Officer and Member of the Board of Wyeth K.K. during his tenure in Japan. He joined United Biomedical, Inc. in 1993 leading the earliest international clinical development of HIV vaccines, initiating clinical trials in China, Australia, and Thailand. At Chiron Corporation he was the global clinical team leader for a meningococcal C conjugate vaccine (Menjugate).

Dr. Forrest is an investment banker with a Westchester, NY-based investment bank (Young America Capital, LLC) where he co-heads Life Sciences Investment Banking. He also owns an independent FINRA-registered investment advisory firm that is regulated by the State of New York (Aeolian Advisors Corp.).